Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do we need a new classification of beta-blockers?

M J Kendall1

  • 1Department of Medicine, Queen Elizabeth Hospital, Birmingham, UK.

Journal of Human Hypertension
|June 1, 1990
PubMed
Summary

Beta-blockers have evolved from non-selective to beta 1-selective drugs, reducing adverse effects like bronchospasm. Newer agents offer mild beta 2-receptor stimulation, further improving safety profiles for beta-blocker therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Charles Dickens' favourite child and a new kind of ray.

Journal of clinical pharmacy and therapeutics·2016
Same author

Experimentally simulating high-rate behaviour: rate and temperature effects in polycarbonate and PMMA.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2014
Same author

Mechanics of particulate composites with glassy polymer binders in compression.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2014
Same author

Availability of methaqualone from commercial preparations: in vitro and in vivo studies in man.

British journal of clinical pharmacology·2012
Same author

An assessment of gastric emptying by breathalyser.

British journal of clinical pharmacology·2012
Same author

The influence of diphenhydramine on the absorption of methaqualone in man.

British journal of clinical pharmacology·2012

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Beta-adrenoceptor blocking drugs (beta-blockers) have been used clinically for 25 years.
  • Early beta-blockers like propranolol were non-selective, blocking both beta 1- and beta 2-receptors.
  • Limited clinical relevance was found for properties like membrane stabilizing activity and partial agonism.

Purpose of the Study:

  • To review the evolution of beta-blocker pharmacology and clinical relevance.
  • To highlight the challenges posed by non-selective beta-blocker side effects, particularly on beta 2-receptors.
  • To discuss the development and benefits of beta 1-selective beta-blockers.

Main Methods:

  • Review of historical and pharmacological data on beta-blocker development.
  • Analysis of clinical implications of beta-receptor blockade.
  • Comparison of non-selective versus selective beta-blocker effects.

Main Results:

  • Non-selective beta-blockers can cause significant adverse effects, notably bronchospasm due to beta 2-receptor blockade.
  • Relatively beta 1-selective beta-blockers (e.g., metoprolol, atenolol) reduce but do not eliminate beta 2-related side effects.
  • Dose and concentration-dependent effects on beta 2-receptors persist even with selective agents.

Conclusions:

  • Beta 1-selective agents offer improved therapeutic benefits with fewer unwanted effects compared to non-selective beta-blockers.
  • The development of drugs with partial agonist activity at beta 2-receptors represents a further advancement.
  • Ongoing research aims to optimize beta-blocker therapy by balancing efficacy and safety profiles.

Related Experiment Videos